Clinical Trials: Non-Small Cell Lung Cancer

Arizona

Phoenix; Hematology Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Scottsdale; Hematology Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

California

Beverly Hills; Tower Cancer Research Foundation
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Beverly Hills; Tower Cancer Research Foundation
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Concord; Bay Area Cancer Research Group
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation

Concord; Bay Area Cancer Research Group, LLC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Duarte; City of Hope
PHII-70 NCI #7077: Randomized Phase II Trial of Sequential versus Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443) in Previously Treated Non-Small Cell Lung Cancer

Duarte; City of Hope
PHII-82-NCI #7863: Randomized Phase II Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Duarte; City of Hope
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non Small Cell Lung Cancer

Duarte; City of Hope
OSI Radiant: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR Positive Tumors

Duarte; City of Hope
ACOSOG Z4032: A Randomzied Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller

Duarte; City of Hope
RTOG 0320: A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non Small Cell Lung Cancer and 1-3 Brain Metastases

Duarte; City of Hope
A Phase II Multicenter, Open Label , Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non Squamous Non Small Cell Lung Cancer

Duarte; City of Hope
SWOG S0424: Molecular Epidemiology Case-Series Study of NSCLC in Smoking and Non-Smoking Women and Men

Duarte; City of Hope
A Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination with Erlotinib in Non-Small Cell Lung Cancer in Patients

Greenbrae; California Cancer Care
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

La Verne; Wilshire Oncology Medical Group, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Orange ; Medical Oncology Care Associates
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Colorado

Aurora; University of Colorado Health Sciences Center
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation

Connecticut

New Milford; Connecticut Oncology & Hematology
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

New Milford; Connecticut Oncology & Hematology, LLP
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Sharon; Connecticut Oncology & Hematology, LLP
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Stamford; Hematology Oncology, P.C., WIRB USA
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Torrington; Connecticut Oncology & Hematology
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Torrington; Connecticut Oncology & Hematology, LLP
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Florida

Gainesville; Gainesville Hematology/Oncology Associates
Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer

Hudson; Florida Cancer Institute
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Lady Lake; Ocala Oncology Center (Lady Lake)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Lakeland; Center for Cancer Care & Research
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Lakeland; Watson Clinic Center for Research, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Miami; Advanced Medical Specialties
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

New Port Richey; Florida Cancer Institute
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Ocala; Ocala Oncology Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Pensacola; Hematology-Oncology Assoc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Port Saint Lucie; Hematology/Oncology Associates of The Treasure Coast
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Georgia

Atlanta; Peachtree Hematology-Oncology Consultants, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Atlanta; Atlanta Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Macon; Central Georgia Cancer Care, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Marietta; Northwest Georgia Oncology Centers, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Illinois

Alton; Hematology Oncology Consultants, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Elgin; Sherman Health Systems
SWOG S0536 "A phase II trial of combination carboplatin, paclitaxel, cetuximab and bevacizumab (NSC-704865) followed by cetuximab and bevacizumab in patients with advanced non-small cell lung cancer"

Elgin; Sherman Health Systems
ECOG E5597 "Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer Patients who have undergone complete resection of a histologically proven stage IA(pT1N0) or stage IB(pT2N0)non-small cell lung cancer

Joliet; Joliet Oncology-Hematology Associates, Ltd.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Indiana

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II; Second Line Treatment

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase III; Second Line Treatment

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II; Second Line Treatment (no limit on number of prior treatments)

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II: First Line Treatment Randomized Trial of Paclitaxel, Carboplatin and Bevacizumab with or without study drug for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Fishers; Central Indiana Cancer Centers
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Greenfield; Central Indiana Cancer Centers
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Indianapolis; Central Indiana Cancer Centers
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Indianapolis; Central Indiana Cancer Centers
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Kentucky

Lexington; University of Kentucky Chandler Medical Center
Volunteers Needed for Lung Cancer Vaccine Research Study

Louisville; Norton Healthcare, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Paducah; Oncology Associates of West Kentucky
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Maine

Scarborough; Maine Center for Cancer Medicine
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Maryland

Baltimore; Johns Hopkins Unv., School of Medicine
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Baltimore; Johns Hopkins Unv. School of Med., Sidney Kimmel Comprehensive Cancer Center
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Columbia; Maryland Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Michigan

Detroit; Henry Ford Health System
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Minnesota

Burnsville; Minnesota Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Edina; Minnesota Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Maplewood; Minnesota Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Minneapolis; Minnesota Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Minneapolis; Metro Minnesota CCOP
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

St. Paul; Minnesota Oncology Hematology
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Woodbury; Minnesota Oncology Hematology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Mississippi

Tupelo; North MS Hematology + Oncology Assoc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Tupelo; North MS Hematology + Oncology Assoc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Tupelo; North MS Hematology + Oncology Assoc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Missouri

Columbia; Missouri Cancer Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

St. Louis; Washington University School of Medicine - Barnes Jewish Hospital
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

St. Louis; Hematology Oncology Consultants, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

St. Louis; Arch Medical Services, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Washington; Arch Medical Services, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Montana

Billings; Hematology Oncology Centers of Northern Rockies Research
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Nebraska

Omaha; Alegent Healthcare
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation

Omaha; Methodist Estabrook Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

New Hampshire

Concord; NH Oncology-Hematology PA (Co)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Hocksett; NH Oncology-Hematology PA (Ho)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

New Jersey

Morristown; Hematology-Oncology Associates of NNJ, P
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Paramus; The Valley Hospital/Valley Health System
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Paramus; The Valley Hospital/Valley Health System
Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller

New York

Albany; Albany Medical Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Albany; New York Oncology Hematology, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Amsterdam; Amsterdam Community Cancer Program
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Brockport; Interlakes Oncology Hematology, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Bronx; Montefiore Medical Center
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Canandaigua; Interlakes Oncology Hematology, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Geneva; Interlakes Oncology Hematology, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Hudson; Cavell Cancer Treatment Program
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Jamaica; Biomedical Research Alliance of New York
A study to compare bevacizumab with or without erlotinib for subjects with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Latham; New York Oncology Hematology, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

New York ; Mt. Sinai Medical Center
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Rexford; New York Oncology Hematology, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Rochester; Interlakes Oncology Hematology, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Rochester; Interlakes Oncology Hematology, PC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Schenectady; New York Oncology Hematology, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Staten Island; Richmond University Medical Center
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Staten island; Biomedical Research Alliance of New York
Non Small Cell Lung Cancer (NSCLC) - Adults and minors

Troy; Troy Cancer Treatment Program
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

North Carolina

Cary; Raleigh Hematology Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Charlotte; Clinworks Research Center
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Huntersville; Carolina BioOncology Institute
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR 2797 and Erlotinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Huntersville; Carolina BioOncology Institute, PLLC
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Raleigh; Raleigh Hematology Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Raleigh; Raleigh Hematology Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Raleigh; Rex Healthcare
Randomized Phase II Study of First-Line Treatment with Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients with Stage (IIIB/IV) Non-Small Cell Lung Cancer

Ohio

Canton; Gabrail Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Columbus; Research Site:
A Study of Epothilone D in Patients With Non-Small Cell Lung Cancer (NSCLC)

Columbus; Hematology Oncology Consultants Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Kettering; Greater Dayton Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Oregon

Portland; Providence Portland Medical
This is a phase II clinical trial for patients who are newly diagnosed with Stage IIIA-IIIB non-small cell lung cancer.

Portland; Earle A. Chiles Research Institute
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation

Portland; Northwest Cancer Specialists-Rose Qtr
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Portland; Northwest Cancer Specialists-Rose Qtr
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Portland; Northwest Cancer Specialists-Northrup
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Portland; Northwest Cancer Specialists-St. Vincent
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Pennsylvania

Bethlehem; Oncology Hematology of Lehigh Valley, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Kingston; Medical Oncology Associates
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

South Carolina

Columbia; South Carolina Oncology Assoc., PA
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Easley; Cancer Centers of the Carolinas
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Greenville; Cancer Centers of the Carolinas
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Greenville; Cancer Centers of the Carolinas
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Seneca; Cancer Centers of the Carolinas, Seneca
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Spartanburg; Cancer Centers of the Carolinas
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Tennessee

Collierville; Family Cancer Center, P.L.L.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Collierville; Family Cancer Center, P.L.L.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Collierville; Family Cancer Center, PLLC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Knoxville; Baptist Regional Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Memphis; Family Cancer Center, PLLC
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Memphis; West Clinic
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Texas

Abilene; Texas Cancer Center - Abilene (S)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Amarillo; Texas Oncology, P.A. - Amarillo
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Arlington; Texas Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Austin; South Austin Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Austin; Texas Oncology Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Beaumont; Mamie McFaddin Ward Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Dallas; Texas Cancer Center at Medical City
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Dallas; Methodist Charlton Cancer Ctr.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Dallas; Texas Oncology, PA
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Fort Worth; Southwest Fort Worth Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Ft. Worth; Texas Oncology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Garland; Texas Oncology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Lewisville; Lake Vista Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Longview; Longview Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Paris; Paris Regional Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Plano; North Texas Regional Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Round Rock; Texas Cancer Center - Round Rock
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Tyler; Tyler Cancer Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Waco; Texas Oncology Cancer Care and Researh Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Webster; Texas Oncology, P.A.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Virginia

Chesapeake; Cancer Specialists of Tidewater, Ltd. Research
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Christiansburg; Onc and Hem Associates of SW VA, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Christiansburg; Onc and Hem Associates of SW VA, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Danville; Danville Hematology and Oncology, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Roanoke; Onc and Hem Associates of SW VA, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Salem; Onc and Hem Assoc of SW VA, Inc
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Wytheville; Onc and Hem Associates of SW VA, Inc.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Washington

Edmonds; Puget Sound Cancer Center-Edmonds
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Seattle; Fred Hutchinson Cancer Research Center
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Spokane; Cancer Care Northwest-Valley
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Spokane; Cancer Care Northwest-South
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Spokane; Cancer Care Northwest-North
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Vancouver; Northwest Cancer Specialists-Vancouver
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Vancouver; Northwest Cancer Specialists, P.C.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

Yakima; Yakima Valley Mem Hosp/North Star Lodge
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.

International

Tirana, Albania; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bahia Blanca, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Buenos Aires , Argentina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Buenos Aires , Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Buenos Aires , Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Chaco-Resistencia, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Córdoba, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Córdoba, Argentina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

La Plata, Argentina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Mendoza, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Salta, Argentina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

San Miguel De Tucuman, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Santa Fe, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Santa Fe, Argentina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Tucuman, Argentina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Adelaide, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Adelaide, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Adelaide, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Adelaide, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Auchenflower, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Brisbane, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Brisbane, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Brisbane, Australia; Research Site:
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).

Brisbane, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Campbelltown, Australia; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Canberra, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Chermside, Australia; Research Site:
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).

Chermside, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Chermside, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Fitzroy, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Fitzroy, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Frankston, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Fremantle, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Geelong, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Geelong, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Geelong, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Geelong, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Geelong, Australia; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Greenslopes, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Heidelberg, Australia; Research Site:
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).

Lismore, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Liverpool, Australia; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Malvern, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Malvern, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Melbourne, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Melbourne, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Melbourne, Australia; Research Site:
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).

Melbourne, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Melbourne, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Melbourne, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Melbourne, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Melbourne, Australia; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Parkville, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Parkville, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Perth, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Perth, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Perth, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Randwick, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Richmond, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

St. Leonards, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

St. Leonards, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

St. Leonards, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

St. Leonards, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

St. Leonards, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Sydney, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Sydney, Australia; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Sydney, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sydney, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sydney, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Tugun, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer.

Tugun, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Tugun, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Tugun, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Waratah, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Waratah, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Waratah, Australia; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Waratah, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Wodonga, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wodonga, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Wodonga, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Wollongong, Australia; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Wollongong, Australia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wollongong, Australia; Research Site:
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Bludenz, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Bludesch, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Bludesch, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bregenz, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Dornbirn, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Graz, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Grimmenstein, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hall In Tirol, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Hohenems, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Innsbruck, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Innsbruck, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Innsbruck, Austria; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Innsbruck, Austria; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Klagenfurt, Austria; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Klagenfurt, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Klagenfurt, Austria; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Knittelfeld, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Kufstein, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Kufstein, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Leoben, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Leoben, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Linz, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Linz, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Natters, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Natters, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Oberpullendorf, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Ried-Innkreis, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Salzburg, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Salzburg, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

St Pölten, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

St Veit an der Glan, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Steyr, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Vöcklabruck, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Vöcklabruck, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wels, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Wels, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wien, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Wien, Austria; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Wien, Austria; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Wien, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wiener Neustadt, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Zams, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Zams, Austria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Aalst, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Antwerpen, Belgium; Research Site:
A Study of Pertuzumab in Combination With Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Antwerpen, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Antwerpen, Belgium; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Antwerpen, Belgium; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Arlon, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Baudour, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Blankenberge, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Borgerhout, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Boussu, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Brasschaat, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bruxelles, Belgium; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Bruxelles, Belgium; Research Site:
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Bruxelles, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Charleroi, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Edegem, Belgium; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Edegem, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Genk, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Gent, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Gilly, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Godinne, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Gosselies, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Haine-Saint-Paul, Belgium; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Haine-Saint-Paul, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hasselt, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Kortrijk, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Leuven, Belgium; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Leuven, Belgium; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Libramont, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Liege, Belgium; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Liege, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Mons, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Namur, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Oostende, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Ottignies, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Oudenaarde, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Roeselare, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sint-Niklaas, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Tielt, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Tournai, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Turnhout, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wilrijk, Belgium; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Banja Luka, Bosnia and Herzegovina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Banja Luka, Bosnia and Herzegovina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sarajevo, Bosnia and Herzegovina; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sarajevo, Bosnia and Herzegovina; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Belo Horizonte, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Belo Horizonte, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Belo Horizonte, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Brasilia, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Campinas, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Campinas, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Caxias do Sul, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Curitiba, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Curitiba, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Florianopolis, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Fortaleza, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Fortaleza, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Goiania, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Ijuí, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Ijuí, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Jaú, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Jaú, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Niteroi, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Piracicaba, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Porto Alegre, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Porto Alegre, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Porto Alegre, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recife, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Recife, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Ribeirão Preto, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Ribeirão Preto, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Rio De Janeiro, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Rio De Janeiro, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Rio De Janeiro, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Salvador, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Salvador, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Santos, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Santos, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sao Paulo, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Sao Paulo, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sao Paulo, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sorocaba, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Sorocaba, Brazil; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Vitoria, Brazil; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Plovdiv, Bulgaria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Plovdiv, Bulgaria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Sofia, Bulgaria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Sofia, Bulgaria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sofia, Bulgaria; Research Site:
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Stara Zagora, Bulgaria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Varna, Bulgaria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Varna, Bulgaria; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Veliko Tarnovo, Bulgaria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Calgary, AB, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Calgary, Alberta, Canada; Dr. Gwynn Bebb
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Edmonton, AB, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Greenfield Park, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Halifax, Nova Scotia, Canada; QE II Centre for Clinical Research
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Laval, QC, Canada; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Laval, QC, Canada; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

London, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

London, Ontario, Canada; Dr. Mark Vincent
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Mississauga, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Moncton, NB, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Montreal, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Montreal, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Montreal, QC, Canada; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Montreal, QC, Canada; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Newmarket, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Newmarket, Ontario, Canada; Oncology Clinical Trials Southlake Regional Health Centre
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Oshawa, ON, Canada; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Oshawa, ON, Canada; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Oshawa, ON, Canada; Dr. Rafal Wierzbicki
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Sainte-Foy, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Sault Ste. Marie, ON, Canada; Algoma Regional Cancer Program
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Thunder Bay, ON, Canada; Thunder Bay Regional Health Sciences Centre
A clinical trial where the effect of a new treatment is investigated in patients with Non Small Cell Lung Cancer.

Toronto, ON, Canada; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Toronto, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Vancouver, BC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Victoria, BC, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Weston, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Winnipeg, MB, Canada; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Santiago, Chile; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Santiago, Chile; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Santiago, Chile; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Beijing, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Beijing, China; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Beijing, China; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Beijing, China; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Chengdu, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Guangzhou, China; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Guangzhou, China; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Guangzhou, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Guangzhou, China; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Guangzhou, China; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hangzhou, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hangzhou, China; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Harbin, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hong Kong, China; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Hong Kong, China; Research Site:
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Hong Kong, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hong Kong, China; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Hong Kong, China; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Nanjing, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Shanghai, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Shanghai, China; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Shanghai, China; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Shanghai, China; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Shanghai, China; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Tianjin, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Wuhan, China; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bogota, Colombia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bogota, Colombia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Cali, Colombia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Cali, Colombia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Manizales, Colombia; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Zagreb, Croatia; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Brno, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Brno, Czech Republic; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Ceské Budejovice, Czech Republic; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Ceské Budejovice, Czech Republic; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hradec Kralove, Czech Republic; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Olomouc, Czech Republic; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Olomouc, Czech Republic; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Olomouc, Czech Republic; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Ostrava, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Plzen, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Plzen, Czech Republic; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Praha, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Praha, Czech Republic; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Praha, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Usti Nad Labem, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Usti Nad Labem, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer.

Århus, Denmark; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Herlev, Denmark; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Herlev, Denmark; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Herlev, Denmark; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hillerød, Denmark; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Naestved, Denmark; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Odense, Denmark; Research Site:
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Odense, Denmark; Research Site:
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Guayaquil, Ecuador; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Guayaquil, Ecuador; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Quito, Ecuador; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Quito, Ecuador; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Cairo, Egypt; Research Site:
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

<